Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 371

1.

Mutational screening of inverted formin 2 in adult-onset focal segmental glomerulosclerosis or minimal change patients from the Czech Republic.

Safarikova M, Stekrova J, Honsova E, Horinova V, Tesar V, Reiterova J.

BMC Med Genet. 2018 Aug 20;19(1):147. doi: 10.1186/s12881-018-0667-9.

PMID:
30126379
2.

Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.

Hruskova Z, Pippias M, Stel VS, Abad-Díez JM, Benítez Sánchez M, Caskey FJ, Collart F, De Meester J, Finne P, Heaf JG, Magaz A, Palsson R, Reisæter AV, Salama AD, Segelmark M, Traynor JP, Massy ZA, Jager KJ, Tesar V.

Am J Kidney Dis. 2018 Aug 16. pii: S0272-6386(18)30768-6. doi: 10.1053/j.ajkd.2018.05.016. [Epub ahead of print]

PMID:
30122544
3.

Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus.

Hruskova Z, Tesar V.

Expert Opin Biol Ther. 2018 Jul 31:1-8. doi: 10.1080/14712598.2018.1504918. [Epub ahead of print]

PMID:
30040494
4.

Bilineal inheritance of pathogenic PKD1 and PKD2 variants in a Czech family with autosomal dominant polycystic kidney disease - a case report.

Elisakova V, Merta M, Reiterova J, Baxova A, Kotlas J, Hirschfeldova K, Obeidova L, Tesar V, Stekrova J.

BMC Nephrol. 2018 Jul 4;19(1):163. doi: 10.1186/s12882-018-0978-2.

5.

Avacopan in the treatment of ANCA-associated vasculitis.

Tesar V, Hruskova Z.

Expert Opin Investig Drugs. 2018 May;27(5):491-496. doi: 10.1080/13543784.2018.1472234. Epub 2018 May 8. Review.

PMID:
29718732
6.

Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Weiner M, Bjørneklett R, Hrušková Z, Mackinnon B, Poulton CJ, Sindelar L, Mohammad AJ, Eriksson P, Gesualdo L, Geetha D, Crnogorac M, Jayne D, Hogan SL, Geddes C, Tesar V, Aasarød K, Segelmark M.

Nephrol Dial Transplant. 2018 Apr 30. doi: 10.1093/ndt/gfy106. [Epub ahead of print]

PMID:
29718465
7.

Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy.

Coppo R, Peruzzi L, Loiacono E, Bergallo M, Krutova A, Russo ML, Cocchi E, Amore A, Lundberg S, Maixnerova D, Tesar V, Perkowska-Ptasinska A, Durlik M, Goumenos D, Gerolymos M, Galesic K, Toric L, Papagianni A, Stangou M, Mizerska-Wasia Membek M, Gesualdo L, Montemurno E, Benozzi L, Cusinato S, Hryszko T, Klinger M, Kaminska D, Krajewska M; VALIGA Study Group of the ERA-EDTA Immunonephrology Working Group.

Nephrol Dial Transplant. 2018 Apr 9. doi: 10.1093/ndt/gfy064. [Epub ahead of print]

PMID:
29635535
8.

Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.

Čertíková Chábová V, Kujal P, Škaroupková P, Varňourková Z, Vacková Š, Husková Z, Kikerlová S, Sadowski J, Kompanowska-Jezierska E, Baranowska I, Hwang SH, Hammock BD, Imig JD, Tesař V, Červenka L.

Kidney Blood Press Res. 2018;43(2):329-349. doi: 10.1159/000487902. Epub 2018 Mar 6.

9.

Management of Elderly Patients with Rapidly Progressive Glomerulonephritis.

Hruskova Z, Tesar V.

Blood Purif. 2018;45(1-3):213-217. doi: 10.1159/000485368. Epub 2018 Jan 26.

10.

Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis.

Tycová I, Hrubá P, Maixnerová D, Girmanová E, Mrázová P, Straňavová L, Zachoval R, Merta M, Slatinská J, Kollár M, Honsová E, Tesař V, Viklický O.

Physiol Res. 2018 Mar 16;67(1):93-105. Epub 2017 Nov 10.

11.

[Gliflozins slow down the progression of diabetic kidney disease].

Tesař V, Vachek J.

Vnitr Lek. Fall 2017;63(10):723-727. Review. Czech.

PMID:
29127757
12.

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts.

Yates M, Watts R, Bajema I, Cid M, Crestani B, Hauser T, Hellmich B, Holle J, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel P, Mills J, Mooney J, Segelmark M, Tesar V, Westman KWA, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

RMD Open. 2017 Jun 15;3(1):e000449. doi: 10.1136/rmdopen-2017-000449. eCollection 2017.

13.

Pregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis.

Kalousová M, Dusilová-Sulková S, Kuběna AA, Zakiyanov O, Levová K, Bocková M, Gedeonová E, Song XC, Ermini ML, Špringer T, Homola J, Tesař V, Zima T.

Kidney Blood Press Res. 2017;42(3):509-518. doi: 10.1159/000479847. Epub 2017 Aug 30.

14.

Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.

Tesar V, Ciechanowski K, Pei Y, Barash I, Shannon M, Li R, Williams JH, Levisetti M, Arkin S, Serra A.

J Am Soc Nephrol. 2017 Nov;28(11):3404-3413. doi: 10.1681/ASN.2016111232. Epub 2017 Aug 24.

PMID:
28838955
15.

Immunosuppressive Treatment in C3 Glomerulopathy: Time to Reconsider Our Approach.

Tesar V, Hruskova Z.

Am J Nephrol. 2017;46(2):93-95. doi: 10.1159/000479014. Epub 2017 Jul 13. No abstract available.

16.

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.

McAdoo SP, Tanna A, Hrušková Z, Holm L, Weiner M, Arulkumaran N, Kang A, Satrapová V, Levy J, Ohlsson S, Tesar V, Segelmark M, Pusey CD.

Kidney Int. 2017 Sep;92(3):693-702. doi: 10.1016/j.kint.2017.03.014. Epub 2017 May 12.

17.

Understanding Histolopathologic Characteristics to Predict Renal Outcomes in Lupus Nephritis.

Tesar V, Hruskova Z.

Clin J Am Soc Nephrol. 2017 May 8;12(5):711-712. doi: 10.2215/CJN.03490317. Epub 2017 May 4. No abstract available.

18.

Belimumab in the management of systemic lupus erythematosus - an update.

Tesar V, Hruskova Z.

Expert Opin Biol Ther. 2017 Jul;17(7):901-908. doi: 10.1080/14712598.2017.1324846. Epub 2017 May 16. Review.

PMID:
28460578
19.

Proteomic approach for identification of IgA nephropathy-related biomarkers in urine.

Prikryl P, Vojtova L, Maixnerova D, Vokurka M, Neprasova M, Zima T, Tesar V.

Physiol Res. 2017 Sep 22;66(4):621-632. Epub 2017 Apr 12.

20.

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati I, Tesař V, Segelmark M, Potarca A, Schall TJ, Bekker P; CLEAR Study Group.

J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11.

PMID:
28400446
21.

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators.

Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28.

PMID:
28363480
22.

[Current options of treatment of hyponatremia].

Tesař V.

Vnitr Lek. 2016 Winter;62 Suppl 6:97-101. Czech.

PMID:
28124939
23.

[Gitelman´s syndrome as common cause of hypokalemia and hypomagnesemia].

Ryšavá R, Reiterová J, Urbanová M, Štekrová J, Lněnička P, Tesař V.

Vnitr Lek. 2016 Winter;62 Suppl 6:78-83. Czech.

PMID:
28124936
24.

[Theralite and multiple myeloma].

Lachmanová J, Tesař V, Ryšavá R, Bartková M.

Vnitr Lek. 2016 Winter;62 Suppl 6:9-13. Czech.

PMID:
28124926
25.

Tissue ischemia worsens during hemodialysis in end-stage renal disease patients.

Malik J, Kudlicka J, Lachmanova J, Valerianova A, Rocinova K, Bartkova M, Tesar V.

J Vasc Access. 2017 Jan 18;18(1):47-51. doi: 10.5301/jva.5000630. Epub 2016 Nov 22.

PMID:
27886367
26.

NETosis provides the link between activation of neutrophils on hemodialysis membrane and comorbidities in dialyzed patients.

Korabecna M, Tesar V.

Inflamm Res. 2017 May;66(5):369-378. doi: 10.1007/s00011-016-1010-6. Epub 2016 Nov 24. Review.

27.

Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study.

Neprasova M, Maixnerova D, Novak J, Reily C, Julian BA, Boron J, Novotny P, Suchanek M, Tesar V, Kacer P.

Dis Markers. 2016;2016:3650909. Epub 2016 Oct 9.

28.

Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis.

Alberici F, Smith RM, Fonseca M, Willcocks LC, Jones RB, Holle JU, Wieczorek S, Neumann T, Martorana D, Gregorini G, Sinico RA, Bruchfeld A, Gunnarsson I, Ohlsson S, Baslund B, Tesar V, Hruskova Z, Cid MC, Vaglio A, Lyons PA, Smith KGC, Jayne DRW.

J Allergy Clin Immunol. 2017 May;139(5):1684-1687.e10. doi: 10.1016/j.jaci.2016.08.051. Epub 2016 Oct 22. No abstract available.

PMID:
27780742
29.

Erratum to: Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.

Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, Fuiano L, Berg U, Topaloglu R, Bilginer Y, Gesualdo L, Polci R, Mizerska-Wasiak M, Caliskan Y, Lundberg S, Cancarini G, Geddes C, Wetzels J, Wiecek A, Durlik M, Cusinato S, Rollino C, Maggio M, Praga M, Smerud HK, Tesar V, Maixnerova D, Barratt J, Papalia T, Bonofiglio R, Mazzucco G, Giannakakis C, Soderberg M, Orhan D, Di Palma AM, Maldyk J, Ozluk Y, Sudelin B, Tardanico R, Kipgen D, Steenbergen E, Karkoszka H, Perkowska-Ptasinska A, Ferrario F, Gutierrez E, Honsova E.

Pediatr Nephrol. 2017 Jan;32(1):193-194. No abstract available.

30.

Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.

Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, Fuiano L, Berg U, Topaloglu R, Bilginer Y, Gesualdo L, Polci R, Mizerska-Wasiak M, Caliskan Y, Lundberg S, Cancarini G, Geddes C, Wetzels J, Wiecek A, Durlik M, Cusinato S, Rollino C, Maggio M, Praga M, K Smerud H, Tesar V, Maixnerova D, Barratt J, Papalia T, Bonofiglio R, Mazzucco G, Giannakakis C, Soderberg M, Orhan D, Di Palma AM, Maldyk J, Ozluk Y, Sudelin B, Tardanico R, Kipgen D, Steenbergen E, Karkoszka H, Perkowska-Ptasinska A, Ferrario F, Gutierrez E, Honsova E.

Pediatr Nephrol. 2017 Jan;32(1):139-150. Epub 2016 Aug 25. Erratum in: Pediatr Nephrol. 2017 Jan;32(1):193-194.

31.

Lupus Nephritis: A Different Disease in European Patients?

Tesar V, Hruskova Z.

Kidney Dis (Basel). 2015 Sep;1(2):110-8. doi: 10.1159/000438844. Epub 2015 Aug 28. Review.

32.

Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study.

Frausová D, Hrušková Z, Lánská V, Lachmanová J, Tesař V.

Arthritis Res Ther. 2016 Jul 13;18:168. doi: 10.1186/s13075-016-1055-5.

33.

Urine sCD163: a window onto glomerular inflammation.

Møller HJ, Tesar V, Little MA.

Nephrol Dial Transplant. 2016 Dec;31(12):1970-1972. Epub 2016 Jun 29. No abstract available.

PMID:
27358273
34.

Left Atrial Dysfunction in End-Stage Renal Disease Patients Treated by Hemodialysis.

Malik J, Lachmanova J, Kudlicka J, Rocinova K, Valerianova A, Bartkova M, Tesar V.

Nephron. 2016;133(3):169-74. doi: 10.1159/000447500. Epub 2016 Jun 25.

PMID:
27344674
35.

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23.

36.

Moderator's view: Cyclophosphamide in lupus nephritis.

Tesar V.

Nephrol Dial Transplant. 2016 Jul;31(7):1058-61. doi: 10.1093/ndt/gfw067. Epub 2016 May 14.

PMID:
27190357
37.

Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies.

Fiorentino M, Bolignano D, Tesar V, Pisano A, Biesen WV, Tripepi G, D'Arrigo G, Gesualdo L; ERA-EDTA Immunonephrology Working Group.

Nephrol Dial Transplant. 2017 Jan 1;32(1):97-110. doi: 10.1093/ndt/gfw070.

PMID:
27190327
38.

Markers for the progression of IgA nephropathy.

Maixnerova D, Reily C, Bian Q, Neprasova M, Novak J, Tesar V.

J Nephrol. 2016 Aug;29(4):535-41. doi: 10.1007/s40620-016-0299-0. Epub 2016 May 3. Review.

39.

Genome-wide methylation analysis of tubulocystic and papillary renal cell carcinomas.

Korabecna M, Geryk J, Hora M, Steiner P, Seda O, Tesar V.

Neoplasma. 2016;63(3):402-10. doi: 10.4149/309_151102N559.

PMID:
26925785
40.

HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets.

Tesarova P, Kalousova M, Zima T, Tesar V.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):1-10. doi: 10.5507/bp.2016.003. Epub 2016 Feb 3. Review.

41.

Renal Biopsy in 2015--From Epidemiology to Evidence-Based Indications.

Fiorentino M, Bolignano D, Tesar V, Pisano A, Van Biesen W, D'Arrigo G, Tripepi G, Gesualdo L; ERA-EDTA Immunonephrology Working Group.

Am J Nephrol. 2016;43(1):1-19. doi: 10.1159/000444026. Epub 2016 Feb 5. Review.

42.

Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up.

Pesickova SS, Rysava R, Lenicek M, Vitek L, Potlukova E, Hruskova Z, Jancova E, Honsova E, Zavada J, Trendelenburg M, Tesar V.

Arthritis Res Ther. 2015 Dec 24;17:371. doi: 10.1186/s13075-015-0879-8.

43.

Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy.

Feehally J, Coppo R, Troyanov S, Bellur SS, Cattran D, Cook T, Roberts IS, Verhave JC, Camilla R, Vergano L, Egido J, Wiecek A, Karkoszka H, Tesar V, Maixnerova D, Ots-Rosenberg M, Quaglia M, Rollino C, Magistroni R, Cusinato S, Cravero R, Peruzzi L, Lundberg S, Gesualdo L, Cancarini G, Feriozzi S, Ferrario F; VALIGA study of ERA-EDTA Immunonephrology Working Group.

Nephron. 2016;132(1):15-24. doi: 10.1159/000441852. Epub 2015 Nov 20.

PMID:
26586175
44.

A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.

Rojas-Rivera J, Fernández-Juárez G, Ortiz A, Hofstra J, Gesualdo L, Tesar V, Wetzels J, Segarra A, Egido J, Praga M.

Clin Kidney J. 2015 Oct;8(5):503-10. doi: 10.1093/ckj/sfv075. Epub 2015 Sep 24.

45.

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.

de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, Potarca A, Tesar V, Heerspink HJ, Schall TJ; CCX140-B Diabetic Nephropathy Study Group.

Lancet Diabetes Endocrinol. 2015 Sep;3(9):687-96. doi: 10.1016/S2213-8587(15)00261-2. Epub 2015 Aug 9.

PMID:
26268910
46.

Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?

Tesar V, Hruskova Z.

Expert Opin Pharmacother. 2015;16(11):1683-702. doi: 10.1517/14656566.2015.1059822. Epub 2015 Jul 6. Review.

PMID:
26149512
47.

Outcome and treatment of elderly patients with ANCA-associated vasculitis.

Weiner M, Goh SM, Mohammad AJ, Hruskova Z, Tanna A, Bruchfeld A, Selga D, Chocova Z, Westman K, Eriksson P, Pusey CD, Tesar V, Salama AD, Segelmark M.

Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1128-35. doi: 10.2215/CJN.00480115. Epub 2015 Jun 22.

48.

Vitamin D Binding Protein Is Not Involved in Vitamin D Deficiency in Patients with Chronic Kidney Disease.

Kalousova M, Dusilova-Sulkova S, Zakiyanov O, Kostirova M, Safranek R, Tesar V, Zima T.

Biomed Res Int. 2015;2015:492365. doi: 10.1155/2015/492365. Epub 2015 May 4.

49.

Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.

Shah S, Hruskova Z, Segelmark M, Morgan MD, Hogan J, Lee SK, Dale J, Harper L, Tesar V, Jayne DR, Geetha D.

Am J Nephrol. 2015;41(4-5):296-301. doi: 10.1159/000431336. Epub 2015 Jun 2.

50.

Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts.

Pagnoux C, Carette S, Khalidi NA, Walsh M, Hiemstra TF, Cuthbertson D, Langford C, Hoffman G, Koening CL, Monach PA, Moreland L, Mouthon L, Seo P, Specks U, Ytterberg S, Westman K, Hoglund P, Harper L, Flossman O, Luqmani R, Savage CO, Rasmussen N, de Groot K, Tesar V, Jayne D, Merkel PA, Guillevin L; french Vasculitis Study Group (FVSG), European Vasculitis Society (EUVAS) and Vasculitis Clinical Research Consortium (VCRC).

Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-77-83. Epub 2015 May 26.

Supplemental Content

Support Center